We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Henry Schein Inks Agreement for Rijuven's CardioSleeve
Read MoreHide Full Article
Henry Schein, Inc. (HSIC - Free Report) , a distributor of health care products and services, recently signed an exclusive distribution agreement with patient care platform designer Rijuven Corp. The latter develops innovative digital medical devices, one of which is the CardioSleeve diagnostic device. Per the deal, Henry Schein’s medical division will sell Rijuven’s CardioSleeve to clients of medical practitioners.
In coincidence with American Heart Month, Henry Schein’s announcement highlights the availability of modern technology that can help clinicians detect heart disease faster and more accurately.
CardioSleeve is a stethoscope attachment that records synchronized electrocardiogram (ECG) and heart sound signals, transfers real-time data to any smart phone or tablet via Bluetooth and offers cloud-based analysis to help physicians provide diagnostic interpretation of a patient's heart in the office or from remote locations.
The device gives results that are built into a physician's Electronic Health Record system to track patients, review tests and allow practitioners to consult. Detailed PDF reports can be generated and viewed through web access anytime. Various tools built within the mobile application, including digital caliper, trend analysis, cloud patient management, and telehealth connectivity can be used with CardioSleeve.
According to the American Heart Association, more than 85 million Americans experience some form of cardiovascular ailment and half of the sudden cardiac deaths occur outside hospitals. Thus, there is an urgent need to address these problems. Management claims that CardioSleeve helps physicians detect arrhythmias, murmur pathology and heart failure without any difficulty.
Meanwhile, Henry Schein's medical segment continues to grow as North American medical sales were grew 11% on expanding market share in last reported fourth quarter of 2016. The company also recorded 11% year-over-year total growth at the segment during the same quarter. We believe that Henry Schein’s tie up with Rijuven will expand the former’s portfolio of solutions to address cardiovascular diseases and also boost the medical segment in the near term.
Share Price Movement
Over the past three months, Henry Schein traded above the Zacks categorized Medical - Dental Supplies industry. The stock is currently up 12.9%, higher than 8.5% of the broader industry.
Additionally, the company has seen two upward revisions with one downward movement for the current quarter over the last two months. Similarly, for the same period, current year estimates have gone up from $1.61 to $1.63.
Zacks Rank & Key Picks
Henry Schein currently has a Zacks Rank #4 (Sell). Better-ranked medical stocks are Glaukos Corporation (GKOS - Free Report) , Cardiovascular Systems and Neogen Corp. (NEOG - Free Report) . Glaukos sports a Zacks Rank #1 (Strong Buy) while Cardiovascular Systems and Neogen carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Glaukos gained over 100% in the last one year in comparison to the S&P 500’s gain of 22.4%. The company has a stellar four-quarter average earnings surprise of over 100%.
Cardiovascular Systems surged over 100% in the last one year in comparison to the S&P 500. It has a four-quarter average earnings surprise of 67.8%.
Neogen gained 34.1% in the past one year, better than the S&P 500 mark. The stock has an impressive long-term earnings growth rate of 16.7% for the next five years compared to the industry average of 15.2%.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? Last year's market-beating Top 10 portfolio produced 5 double-digit winners. For example, oil and natural gas giant Pioneer Natural Resources and First Republic Bank racked up stellar gains of +44.9% and +44.3% respectively. Now a brand-new list for 2017 has been hand-picked from 4,400 companies covered by the Zacks Rank. See the 2017 Top 10 right now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Henry Schein Inks Agreement for Rijuven's CardioSleeve
Henry Schein, Inc. (HSIC - Free Report) , a distributor of health care products and services, recently signed an exclusive distribution agreement with patient care platform designer Rijuven Corp. The latter develops innovative digital medical devices, one of which is the CardioSleeve diagnostic device. Per the deal, Henry Schein’s medical division will sell Rijuven’s CardioSleeve to clients of medical practitioners.
In coincidence with American Heart Month, Henry Schein’s announcement highlights the availability of modern technology that can help clinicians detect heart disease faster and more accurately.
CardioSleeve is a stethoscope attachment that records synchronized electrocardiogram (ECG) and heart sound signals, transfers real-time data to any smart phone or tablet via Bluetooth and offers cloud-based analysis to help physicians provide diagnostic interpretation of a patient's heart in the office or from remote locations.
Henry Schein, Inc. Price
Henry Schein, Inc. Price | Henry Schein, Inc. Quote
The device gives results that are built into a physician's Electronic Health Record system to track patients, review tests and allow practitioners to consult. Detailed PDF reports can be generated and viewed through web access anytime. Various tools built within the mobile application, including digital caliper, trend analysis, cloud patient management, and telehealth connectivity can be used with CardioSleeve.
According to the American Heart Association, more than 85 million Americans experience some form of cardiovascular ailment and half of the sudden cardiac deaths occur outside hospitals. Thus, there is an urgent need to address these problems. Management claims that CardioSleeve helps physicians detect arrhythmias, murmur pathology and heart failure without any difficulty.
Meanwhile, Henry Schein's medical segment continues to grow as North American medical sales were grew 11% on expanding market share in last reported fourth quarter of 2016. The company also recorded 11% year-over-year total growth at the segment during the same quarter. We believe that Henry Schein’s tie up with Rijuven will expand the former’s portfolio of solutions to address cardiovascular diseases and also boost the medical segment in the near term.
Share Price Movement
Over the past three months, Henry Schein traded above the Zacks categorized Medical - Dental Supplies industry. The stock is currently up 12.9%, higher than 8.5% of the broader industry.
Zacks Rank & Key Picks
Henry Schein currently has a Zacks Rank #4 (Sell). Better-ranked medical stocks are Glaukos Corporation (GKOS - Free Report) , Cardiovascular Systems and Neogen Corp. (NEOG - Free Report) . Glaukos sports a Zacks Rank #1 (Strong Buy) while Cardiovascular Systems and Neogen carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Glaukos gained over 100% in the last one year in comparison to the S&P 500’s gain of 22.4%. The company has a stellar four-quarter average earnings surprise of over 100%.
Cardiovascular Systems surged over 100% in the last one year in comparison to the S&P 500. It has a four-quarter average earnings surprise of 67.8%.
Neogen gained 34.1% in the past one year, better than the S&P 500 mark. The stock has an impressive long-term earnings growth rate of 16.7% for the next five years compared to the industry average of 15.2%.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? Last year's market-beating Top 10 portfolio produced 5 double-digit winners. For example, oil and natural gas giant Pioneer Natural Resources and First Republic Bank racked up stellar gains of +44.9% and +44.3% respectively. Now a brand-new list for 2017 has been hand-picked from 4,400 companies covered by the Zacks Rank. See the 2017 Top 10 right now>>